Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) has provided an announcement.
Hansoh Pharmaceutical Group Company Limited announced that its self-developed HS-10529 tablets, a Small Molecule Category I Innovative Drug targeting KRAS G12D mutations, have received Clinical Trial Approval from the National Medical Products Administration of China. This approval allows the company to proceed with clinical trials for advanced solid tumors, including pancreatic, colorectal, and non-small cell lung cancers, potentially enhancing its market position and offering new treatment options for these conditions.
More about Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited is a pharmaceutical company incorporated in the Cayman Islands, focusing on the development of innovative drugs. The company is involved in the pharmaceutical industry, primarily targeting advanced solid tumors with its innovative products.
YTD Price Performance: 31.94%
Average Trading Volume: 9,497,856
Technical Sentiment Signal: Sell
Current Market Cap: HK$135.3B
Learn more about 3692 stock on TipRanks’ Stock Analysis page.